Antibody Drug Conjugate News and Research

RSS

New mathematical model tracks how tumor environment impacts cancer therapies

Researchers from Mass General Brigham and the University of Cyprus have developed a sophisticated mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC).

30 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy.

14 Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Computational pipeline uncovers subtype specific targets for cervical cancer

A new study presents a multi-layered strategy for identifying cell-surface targets that could help guide more precise antibody-drug conjugate (ADC) development for cervical cancer, with different targets showing distinct potential across tumor subtypes.

17 Aug 2026

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer.

27 Jul 2026

Self-assembling antibody drugs successfully target multiple cancer receptors

Modern anticancer medications that combine tumor-fighting drugs with proteins that specifically target cancer cells are a relatively new class of drug, often given to patients for whom standard chemotherapy has not worked.

15 Jul 2026

Novel leukemia therapy successfully eradicates measurable residual disease

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

7 Jul 2026

German study identifies therapeutic Achilles' heel for advanced colorectal cancer

A team led by researchers from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute has discovered a promising new approach to treating advanced colorectal cancer.

1 Jul 2026

Review outlines key strategies to overcome antibody drug conjugate resistance

The first Antibody-drug conjugate (ADC) was approved overa quarter-century ago, and today more than 20 have reached the clinic.

24 Jun 2026

New human protein atlas maps how cancer rewires the body’s tissues

Researchers created a DIA-MS atlas of 13,609 proteins across 2,856 samples from fetal, healthy adult, paired non-tumor, and tumor tissues. The resource maps tissue-specific protein patterns, cancer-associated changes, organ-specific drug-toxicity signals, and candidate therapeutic targets.

21 Jun 2026

New spatial map reveals treatment vulnerabilities in bladder cancer

Researchers at The University of Texas MD Anderson Cancer Center have developed a spatial map of muscle-invasive bladder cancer, revealing how tumor cell states, immune environments and therapeutic vulnerabilities are organized within tumors.

18 Jun 2026

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

How antibody-drug conjugates are redefining targeted cancer therapy

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but their success depends on better targets, payloads, linkers, dosing, and patient selection. The Cell review shows that next-generation ADCs could widen treatment options, but safety, resistance, tumor heterogeneity, and clinical translation remain major barriers.

19 May 2026

Waters debuts industry-first extended-range MALS detector for UHPLC/UPLC, powering rapid characterization of large molecules

Waters Corporation today announced the launch of the Waters omniDAWN™ Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.

From Waters Corporation 16 Apr 2026

VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug discovery, today announced the formation of its Scientific Advisory Board (SAB), appointing John Lambert as Chair, with Morris Rosenberg and Peter de Waele serving alongside.

From VALANX Biotech 15 Apr 2026

Precision medicine tools offer hope for patients with rare blood cancers

Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.

9 Apr 2026

VALANX Biotech secures €3 million to advance LIV-1 ADC for metastatic triple-negative breast cancer

VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured €3 million to advance its lead antibody-drug conjugate (ADC) program.

From VALANX Biotech 12 Mar 2026

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

11 Feb 2026